Rocket Pharmaceuticals

175 articles about Rocket Pharmaceuticals

• Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral Gene Therapies at the 28th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)

  10/19/2021

  Rocket Pharmaceuticals, Inc., a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, announces data presentations at the 28th Annual Congress of the European Society of Gene & Cell Therapy taking place virtually October 19-22, 2021.

• Rocket Pharmaceuticals to Present at the 2021 Cell & Gene Meeting on the Mesa

  10/7/2021

  Rocket Pharmaceuticals, Inc. today announces that Gaurav Shah, M.D., chief executive officer, will deliver an in-person company presentation at the 2021 Cell & Gene Meeting on the Mesa, being held as a hybrid conference virtually and in Carlsbad, CA.

• Rocket Pharmaceuticals to Participate in the Chardan Virtual 5th Annual Genetic Medicines Conference

  9/30/2021

  Rocket Pharmaceuticals to Participate in the Chardan Virtual 5 th Annual Genetic Medicines Conference

• Rocket Pharmaceuticals Presents Clinical Data from RP-A501 Trial in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2021

  9/14/2021

  Rocket Pharmaceuticals, Inc. today announces an oral presentation of previously disclosed data from the ongoing Phase 1 trial of RP-A501 for the treatment of Danon Disease was given at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2021.

• Rocket Pharmaceuticals Announces Upcoming Danon Disease Presentation at the Heart Failure Society of America Annual Scientific Meeting 2021

  9/10/2021

  Rocket Pharmaceuticals, Inc. today announces that previously disclosed data from the ongoing Phase 1 trial of RP-A501 in Danon Disease will be presented in a late-breaking oral presentation at the upcoming Heart Failure Society of America (HFSA) Annual Scientific Meeting 2021.

• 

  BioSpace Movers & Shakers, Sept. 10

  9/10/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Rocket Pharmaceuticals Appoints Isabel Carmona, J.D., as Chief Human Resources Officer

  9/7/2021

  Rocket Pharmaceuticals, Inc., a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, announces the appointment of Isabel Carmona, J.D., as chief human resources officer and senior vice president.

• Rocket Pharmaceuticals Announces $26.4 Million Private Placement

  8/30/2021

  Rocket Pharmaceuticals, Inc. announces a securities purchase agreement with a fund affiliated with RTW Investments, LP, the Company’s largest shareholder, for the purchase of an aggregate of 812,516 shares of common stock, par value $0.01 per share, at a purchase price of $32.48 per share, the closing price on August 27, 2021, for aggregate gross proceeds of approximately $26.4 million to the Company before offering expenses.

• 

  Clinical Catch-Up: August 16-20

  8/23/2021

  It was another busy week in clinical trial news. Here’s a look.

• Rocket Pharmaceuticals Announces FDA Lifts Clinical Hold on Danon Disease Trial of RP-A501

  8/16/2021

  Rocket Pharmaceuticals, Inc. today announces that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Company’s Phase 1 clinical trial of RP-A501 for the treatment of Danon Disease, allowing patient enrollment to resume.

• 

  Rocket Relaunches Gene Therapy Program as FDA Lifts Clinical Hold

  8/16/2021

  Patient enrollment in the Phase I study will resume, the company announced this morning.

• Rocket Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Progress

  8/9/2021

  Rocket Pharmaceuticals, Inc. today reports financial results for the quarter ending June 30, 2021 and updates on the Company's key pipeline developments, business operations, and upcoming milestones.

• Rocket Pharmaceuticals to Host Conference Call on Aug. 9 at 4:30 p.m. ET to Discuss Second Quarter Results and Recent Business Highlights

  8/3/2021

  Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, will host a conference call and live audio webcast on Monday, Aug. 9, 2021, at 4:30 p.m. ET to report second quarter 2021 financial results and recent business highlights.

• Rocket Pharmaceuticals Presents Positive Clinical Data from Fanconi Anemia, Leukocyte Adhesion Deficiency-I, and Pyruvate Kinase Deficiency Programs at 24th Annual Meeting of the American Society of Gene and Cell Therapy

  5/13/2021

  Rocket Pharmaceuticals Presents Positive Clinical Data from Fanconi Anemia, Leukocyte Adhesion Deficiency-I, and Pyruvate Kinase Deficiency Programs at 24th Annual Meeting of the American Society of Gene and Cell Therapy

• Rocket Pharmaceuticals Reports First Quarter 2021 Financial Results and Highlights Recent Progress

  5/10/2021

  Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today reports financial results for the quarter ending March 31, 2021 and updates on the Company's key pipeline developments, business operations, and upcoming milestones.

• Rocket Pharmaceuticals Announces Upcoming Clinical Data Presentations at the 24th Annual Meeting of the American Society of Gene and Cell Therapy

  4/27/2021

  Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces clinical data presentations at the upcoming 24thAmerican Society of Gene and Cell Therapy (ASGCT) Annual Meeting

• Rocket Pharmaceuticals Reports Positive Long-Term Clinical Data from RP-L201 Trial for the Treatment of Leukocyte Adhesion Deficiency-I at the Clinical Immunology Society 2021 Annual Meeting

  4/14/2021

  New Long-Term Follow-Up Data Demonstrate Durable CD18 Expression, Improved Skin Lesions, and Consistent Peripheral Vector Copy Numbers Up to 18-Months Post-Treatment 

• Rocket Pharmaceuticals Receives EMA Priority Medicines (PRIME) Designation for RP-L201 Gene Therapy for Treatment of Leukocyte Adhesion Deficiency-I

  3/29/2021

  — PRIME Designation to Facilitate Greater EMA Collaboration for Development and Potential Accelerated Regulatory Review in Europe — — LAD-I Program Now Holds All Available Accelerated Regulatory Designations in the U.S. and EU —

• Rocket Pharmaceuticals Announces Updated Positive Preliminary Clinical Data from Phase 1 Trial of RP-L301 for the Treatment of Pyruvate Kinase Deficiency

  3/22/2021

  Updated Data Demonstrate Sustained Improvements in Hemoglobin to Normal Range at 6-months in First Patient and Similar 3-month Improvements in Second Patient Treated

• Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy Designation for RP-L201 Gene Therapy for Leukocyte Adhesion Deficiency-I

  3/9/2021

  — FDA RMAT Designation for RP-L201 to Help Expedite Development and Registration — — Enrollment Complete in Phase 1/2 Clinical Trial of RP-L201 for the Treatment of LAD-I —